High aspartate aminotransferase to alanine aminotransferase ratio on admission as risk factor for poor prognosis in COVID‑19 patients
Fecha
2020Autor
Qin, Cheng
Wei, Yingxin
Lyu, Xiaoyu
Zhao, Bangbo
Feng, Yunlu
Li, Tianhao
Cao, Hongtao
Yang, Xiaoying
Zhou, Xingtong
Wang, Weibin
You, Lei
Wang, Yujun
Documentos PDF
Resumen
This study aimed to analyze aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio
in COVID-19 patients. After exclusion, 567 inpatients were included in this study and separated into
two groups according to their AST/ALT ratio on admission. Death was regarded as poor prognosis in
this study. Of 567 patients, 200 (35.3%) had AST/ALT≥ 1.38. Of the 200 patients, older age (median
age 60 years), myalgia (64 [32%] cases), fatigue (91 [45.5%] cases), some comorbidities and outcomes
were signifcantly diferent from patients with AST/ALT< 1.38. They also had worse chest computed
tomography (CT) fndings, laboratory results and severity scores. Levels of platelet count (OR
0.995, 95% CI [0.992–0.998]) and hemoglobin (OR 0.984, 95% CI [0.972–0.995]) were independently
associated with AST/ALT≥ 1.38 on admission. Furthermore, a high AST/ALT ratio on admission
was an independent risk factor for poor prognosis (OR 99.9, 95% CI [2.1–4280.5]). In subsequent
monitoring, both survivors and non-survivors showed decreased AST/ALT ratio during hospitalization.
In conclusion, high AST/ALT ratio might be the indication of worse status and outcomes in COVID-19
patients.
Enlace al recurso
https://doi.org/10.1038/s41598-020-73575-2Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.